메뉴 건너뛰기




Volumn 21, Issue 2, 2008, Pages 138-145

An overview of chemotherapy-induced peripheral neuropathy

Author keywords

Adverse events; Chemotherapy; Neuropathy, peripheral; Neurotoxicity

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; IMMUNOMODULATING AGENT; IXABEPILONE; LENALIDOMIDE; NAVELBINE; OXALIPLATIN; PACLITAXEL; TAXANE DERIVATIVE; THALIDOMIDE; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; VINDESINE;

EID: 44349181902     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190008315056     Document Type: Review
Times cited : (1)

References (55)
  • 1
    • 4644362706 scopus 로고    scopus 로고
    • Chemotherapy-induced peripheral neuropathy: Pathogenesis and emerging therapies
    • Ocean AJ, Vahdat LT Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support Care Cancer. 2004 ; 12: 619-625.
    • (2004) Support Care Cancer , vol.12 , pp. 619-625
    • Ocean, A.J.1    Vahdat, L.T.2
  • 2
    • 32244438054 scopus 로고    scopus 로고
    • Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy
    • Hausheer FH, Schilsky RL, Bain S., Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006 ; 33: 15-49.
    • (2006) Semin Oncol , vol.33 , pp. 15-49
    • Hausheer, F.H.1    Schilsky, R.L.2    Bain, S.3    Berghorn, E.J.4    Lieberman, F.5
  • 3
    • 0036158822 scopus 로고    scopus 로고
    • Chemotherapy-induced peripheral neuropathy
    • Quasthoff S., Hartung HP Chemotherapy-induced peripheral neuropathy. J Neurol. 2002 ; 249: 9-17.
    • (2002) J Neurol , vol.249 , pp. 9-17
    • Quasthoff, S.1    Hartung, H.P.2
  • 4
    • 0041621727 scopus 로고    scopus 로고
    • Neurotoxic complications of chemotherapy in patients with cancer: Clinical signs and optimal management
    • Verstappen CP, Heimans JJ, Hoekman K., Postma TJ Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs. 2003 ; 63: 1549-1563.
    • (2003) Drugs , vol.63 , pp. 1549-1563
    • Verstappen, C.P.1    Heimans, J.J.2    Hoekman, K.3    Postma, T.J.4
  • 7
    • 1442279918 scopus 로고    scopus 로고
    • Oxaliplatin-induced neurotoxicity: Acute hyperexcitability and chronic neuropathy
    • Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve. 2004 ; 29: 387-392.
    • (2004) Muscle Nerve , vol.29 , pp. 387-392
    • Lehky, T.J.1    Leonard, G.D.2    Wilson, R.H.3    Grem, J.L.4    Floeter, M.K.5
  • 8
    • 0033767619 scopus 로고    scopus 로고
    • Risks and benefits of taxanes in breast and ovarian cancer
    • Michaud LB, Valero V., Hortobagyi G. Risks and benefits of taxanes in breast and ovarian cancer. Drug Saf. 2000 ; 23: 401-428.
    • (2000) Drug Saf , vol.23 , pp. 401-428
    • Michaud, L.B.1    Valero, V.2    Hortobagyi, G.3
  • 10
    • 29144478503 scopus 로고    scopus 로고
    • Peripheral neuropathy: A persisting challenge in paclitaxel-based regimens
    • Mielke S., Sparreboom A., Mross K. Peripheral neuropathy: a persisting challenge in paclitaxel-based regimens. Eur J Cancer. 2006 ; 42: 24-30.
    • (2006) Eur J Cancer , vol.42 , pp. 24-30
    • Mielke, S.1    Sparreboom, A.2    Mross, K.3
  • 11
    • 0347319032 scopus 로고    scopus 로고
    • The taxanes: Toxicity and quality of life considerations in advanced ovarian cancer
    • Guastalla JP, Dieras V. The taxanes: toxicity and quality of life considerations in advanced ovarian cancer. Br J Cancer. 2003 ; 89: 16-22.
    • (2003) Br J Cancer , vol.89 , pp. 16-22
    • Guastalla, J.P.1    Dieras, V.2
  • 12
    • 33645736326 scopus 로고    scopus 로고
    • Peripheral neuropathy induced by microtubule-stabilizing agents
    • Lee JJ, Swain SM Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol. 2006 ; 24: 1633-1642.
    • (2006) J Clin Oncol , vol.24 , pp. 1633-1642
    • Lee, J.J.1    Swain, S.M.2
  • 13
    • 21844480293 scopus 로고    scopus 로고
    • CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour (h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC
    • Seidman AD, Berry D., Cirrincione C., et al. CALGB 9840: phase III study of weekly (W) paclitaxel (P) via 1-hour (h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. J Clin Oncol ASCO Annual Meeting Proceedings. 2004 ; 22: 512.
    • (2004) J Clin Oncol ASCO Annual Meeting Proceedings , vol.22 , pp. 512
    • Seidman, A.D.1    Berry, D.2    Cirrincione, C.3
  • 14
    • 0032751111 scopus 로고    scopus 로고
    • Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National surgical adjuvant breast and bowel project B-26
    • Smith RE, Brown AM, Mamounas EP, et al. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: national surgical adjuvant breast and bowel project B-26. J Clin Oncol. 1999 ; 17: 3403-3411.
    • (1999) J Clin Oncol , vol.17 , pp. 3403-3411
    • Smith, R.E.1    Brown, A.M.2    Mamounas, E.P.3
  • 15
    • 27644562207 scopus 로고    scopus 로고
    • Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer
    • Mielke S., Sparreboom A., Steinberg SM, et al. Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res. 2005 ; 11: 4843-4850.
    • (2005) Clin Cancer Res , vol.11 , pp. 4843-4850
    • Mielke, S.1    Sparreboom, A.2    Steinberg, S.M.3
  • 17
    • 11344275310 scopus 로고    scopus 로고
    • Neurotoxicity of cancer chemotherapy
    • Dropcho EJ Neurotoxicity of cancer chemotherapy. Semin Neurol. 2004 ; 24: 419-426.
    • (2004) Semin Neurol , vol.24 , pp. 419-426
    • Dropcho, E.J.1
  • 18
    • 33744908019 scopus 로고    scopus 로고
    • Neurologic complications of cancer chemotherapy
    • Sul JK, DeAngelis LM Neurologic complications of cancer chemotherapy. Semin Oncol. 2006 ; 33: 324-332.
    • (2006) Semin Oncol , vol.33 , pp. 324-332
    • Sul, J.K.1    Deangelis, L.M.2
  • 19
    • 44349099891 scopus 로고    scopus 로고
    • Neurological toxicities associated with cancer chemotherapeutic agents
    • Slade JH Neurological toxicities associated with cancer chemotherapeutic agents. US Pharm. 2005 ; 4: 3-18.
    • (2005) US Pharm , vol.4 , pp. 3-18
    • Slade, J.H.1
  • 20
    • 34548417669 scopus 로고    scopus 로고
    • Neuropathy in multiple myeloma treated with thalidomide: A prospective study
    • Plasmati R., Pastorelli F., Cavo M., et al. Neuropathy in multiple myeloma treated with thalidomide: a prospective study. Neurology. 2007 ; 69: 573-581.
    • (2007) Neurology , vol.69 , pp. 573-581
    • Plasmati, R.1    Pastorelli, F.2    Cavo, M.3
  • 21
    • 2942737155 scopus 로고    scopus 로고
    • Thalidomide neuropathy: Too much or too long
    • Apfel SC, Zochodne DW Thalidomide neuropathy: too much or too long. Neurology. 2004 ; 62: 2158-2159.
    • (2004) Neurology , vol.62 , pp. 2158-2159
    • Apfel, S.C.1    Zochodne, D.W.2
  • 22
    • 33749051832 scopus 로고    scopus 로고
    • Development of neuropathy in patients with myeloma treated with thalidomide: Patterns of occurrence and the role of electrophysiologic monitoring
    • Mileshkin L., Stark R., Day B., Seymour JF, Zeldis JB, Prince HM Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol. 2006 ; 24: 4507-4514.
    • (2006) J Clin Oncol , vol.24 , pp. 4507-4514
    • Mileshkin, L.1    Stark, R.2    Day, B.3    Seymour, J.F.4    Zeldis, J.B.5    Prince, H.M.6
  • 23
    • 0036446745 scopus 로고    scopus 로고
    • Incidence and risk factors for thalidomide neuropathy: A prospective study of 135 dermatologic patients
    • Bastuji-Garin S., Ochonisky S., Bouche P., et al. Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. J Invest Dermatol. 2002 ; 119: 1020-1026.
    • (2002) J Invest Dermatol , vol.119 , pp. 1020-1026
    • Bastuji-Garin, S.1    Ochonisky, S.2    Bouche, P.3
  • 25
    • 44349115124 scopus 로고    scopus 로고
    • Cambridge, MA : Millennium Pharmaceuticals Inc;
    • Velcade [prescribing information]. Cambridge, MA: Millennium Pharmaceuticals Inc ; 2007.
    • (2007) Velcade [Prescribing Information]
  • 26
    • 31444442200 scopus 로고    scopus 로고
    • A practical update on the use of bortezomib in the management of multiple myeloma
    • San Miguel J., Blade J., Boccadoro M., et al. A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist. 2006 ; 11: 51-61.
    • (2006) Oncologist , vol.11 , pp. 51-61
    • San Miguel, J.1    Blade, J.2    Boccadoro, M.3
  • 27
    • 33746010219 scopus 로고    scopus 로고
    • Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib
    • Richardson PG, Briemberg H., Jagannath S., et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006 ; 24: 3113-3120.
    • (2006) J Clin Oncol , vol.24 , pp. 3113-3120
    • Richardson, P.G.1    Briemberg, H.2    Jagannath, S.3
  • 28
    • 21344435052 scopus 로고    scopus 로고
    • PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma
    • Oakervee HE, Popat R., Curry N., et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005 ; 129: 755-762.
    • (2005) Br J Haematol , vol.129 , pp. 755-762
    • Oakervee, H.E.1    Popat, R.2    Curry, N.3
  • 29
    • 21344469223 scopus 로고    scopus 로고
    • Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma
    • Jagannath S., Durie B., Wolf J., et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol. 2005 ; 129: 776-783.
    • (2005) Br J Haematol , vol.129 , pp. 776-783
    • Jagannath, S.1    Durie, B.2    Wolf, J.3
  • 30
    • 33750953054 scopus 로고    scopus 로고
    • Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: Results of an IFM phase II study
    • Harousseau JL, Attal M., Leleu X., et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica. 2006 ; 91: 1498-1505.
    • (2006) Haematologica , vol.91 , pp. 1498-1505
    • Harousseau, J.L.1    Attal, M.2    Leleu, X.3
  • 31
    • 34548183776 scopus 로고    scopus 로고
    • Neurotoxicity of bortezomib therapy in multiple myeloma: A single-center experience and review of the literature
    • Badros A., Goloubeva O., Dalal JS, et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer. 2007 ; 110: 1042-1048.
    • (2007) Cancer , vol.110 , pp. 1042-1048
    • Badros, A.1    Goloubeva, O.2    Dalal, J.S.3
  • 33
    • 44349169561 scopus 로고    scopus 로고
    • Princeton, NJ: Bristol-Myers Squibb Company;
    • Ixempra [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company ; 2007.
    • (2007) Ixempra [Prescribing Information]
  • 34
    • 36849071808 scopus 로고    scopus 로고
    • Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment
    • Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007 ; 25: 5210-5217.
    • (2007) J Clin Oncol , vol.25 , pp. 5210-5217
    • Thomas, E.S.1    Gomez, H.L.2    Li, R.K.3
  • 35
    • 33846782923 scopus 로고    scopus 로고
    • Neuroprotection during chemotherapy: A systematic review
    • Walker M., Ni O. Neuroprotection during chemotherapy: a systematic review. Am J Clin Oncol. 2007 ; 30: 82-92.
    • (2007) Am J Clin Oncol , vol.30 , pp. 82-92
    • Walker, M.1    Ni, O.2
  • 36
    • 22844448647 scopus 로고    scopus 로고
    • Peripheral neuropathy induced by administration of cisplatin- and paclitaxel-based chemotherapy could it be predicted
    • Argyriou AA, Polychronopoulos P., Koutras A., et al. Peripheral neuropathy induced by administration of cisplatin- and paclitaxel-based chemotherapy could it be predicted ? Support Care Cancer. 2005 ; 13: 647-651.
    • (2005) Support Care Cancer , vol.13 , pp. 647-651
    • Aa, A.1    Polychronopoulos, P.2    Koutras, A.3
  • 37
    • 15944426735 scopus 로고    scopus 로고
    • Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: A potential mechanism for neurotoxicity
    • McDonald ES, Randon KR, Knight A., Windebank AJ Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity. Neurobiol Dis. 2005 ; 18: 305-313.
    • (2005) Neurobiol Dis , vol.18 , pp. 305-313
    • McDonald, E.S.1    Randon, K.R.2    Knight, A.3    Windebank, A.J.4
  • 38
    • 33846404174 scopus 로고    scopus 로고
    • Molecular mechanisms of resistance and toxicity associated with platinating agents
    • Rabik CA, Dolan ME Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007 ; 33: 9-23.
    • (2007) Cancer Treat Rev , vol.33 , pp. 9-23
    • Rabik, C.A.1    Dolan, M.E.2
  • 39
    • 0031899544 scopus 로고    scopus 로고
    • Severe neuropathy after high dose carboplatin in three patients receiving multidrug chemotherapy
    • Heinzlef O., Lotz JP, Roullet E. Severe neuropathy after high dose carboplatin in three patients receiving multidrug chemotherapy. J Neurol Neurosurg Psychiatry. 1998 ; 64: 667-669.
    • (1998) J Neurol Neurosurg Psychiatry , vol.64 , pp. 667-669
    • Heinzlef, O.1    Lotz, J.P.2    Roullet, E.3
  • 40
    • 24944507764 scopus 로고    scopus 로고
    • Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer
    • Jones SE, Erban J., Overmoyer B., et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol. 2005 ; 23: 5542-5551.
    • (2005) J Clin Oncol , vol.23 , pp. 5542-5551
    • Jones, S.E.1    Erban, J.2    Overmoyer, B.3
  • 41
    • 34547447565 scopus 로고    scopus 로고
    • Chronic exposure to paclitaxel diminishes phosphoinositide signaling by calpain-mediated neuronal calcium sensor-1 degradation
    • Boehmerle W., Zhang K., Sivula M., et al. Chronic exposure to paclitaxel diminishes phosphoinositide signaling by calpain-mediated neuronal calcium sensor-1 degradation. Proc Natl Acad Sci USA. 2007 ; 104: 11103-11108.
    • (2007) Proc Natl Acad Sci USA , vol.104 , pp. 11103-11108
    • Boehmerle, W.1    Zhang, K.2    Sivula, M.3
  • 42
    • 1842786064 scopus 로고    scopus 로고
    • Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy
    • Flatters SJ, Bennett GJ Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. Pain. 2004 ; 109: 150-161.
    • (2004) Pain , vol.109 , pp. 150-161
    • Flatters, S.J.1    Bennett, G.J.2
  • 43
    • 20444493101 scopus 로고    scopus 로고
    • Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats
    • Persohn E., Canta A., Schoepfer S., et al. Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. Eur J Cancer. 2005 ; 41: 1460-1466.
    • (2005) Eur J Cancer , vol.41 , pp. 1460-1466
    • Persohn, E.1    Canta, A.2    Schoepfer, S.3
  • 45
    • 32944482677 scopus 로고    scopus 로고
    • Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer
    • Gradishar WJ, Tjulandin S., Davidson N., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005 ; 23: 7794-7803.
    • (2005) J Clin Oncol , vol.23 , pp. 7794-7803
    • Gradishar, W.J.1    Tjulandin, S.2    Davidson, N.3
  • 46
    • 0037309678 scopus 로고    scopus 로고
    • Neurologic complications of cancer therapy
    • Plotkin SR, Wen PY Neurologic complications of cancer therapy. Neurol Clin N Am. 2003 ; 21: 279-318.
    • (2003) Neurol Clin N Am , vol.21 , pp. 279-318
    • Plotkin, S.R.1    Wen, P.Y.2
  • 47
    • 0029801804 scopus 로고    scopus 로고
    • Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel - A phase II study
    • Fazeny B., Zifko U., Meryn S., Huber H., Grisold W., Dittrich C. Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel - a phase II study. Cancer Chemother Pharmacol. 1996 ; 39: 150-156.
    • (1996) Cancer Chemother Pharmacol , vol.39 , pp. 150-156
    • Fazeny, B.1    Zifko, U.2    Meryn, S.3    Huber, H.4    Grisold, W.5    Dittrich, C.6
  • 48
    • 2942729733 scopus 로고    scopus 로고
    • Thalidomide neurotoxicity: Prospective study in patients with lupus erythematosus
    • Briani C., Zara G., Rondinone R., et al. Thalidomide neurotoxicity: prospective study in patients with lupus erythematosus. Neurology. 2004 ; 62: 2288-2290.
    • (2004) Neurology , vol.62 , pp. 2288-2290
    • Briani, C.1    Zara, G.2    Rondinone, R.3
  • 49
    • 0034947693 scopus 로고    scopus 로고
    • Thalidomide neuropathy in patients treated for metastatic prostate cancer
    • Molloy FM, Floeter MK, Syed NA, et al. Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve. 2001 ; 24: 1050-1057.
    • (2001) Muscle Nerve , vol.24 , pp. 1050-1057
    • Molloy, F.M.1    Floeter, M.K.2    Syed, N.A.3
  • 50
  • 51
    • 33748114137 scopus 로고    scopus 로고
    • Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: Phase I clinical trial of three dosing schedules in patients with solid malignancies
    • Sharma RA, Steward WP, Daines CA, Knight RD, O'Byrne HA, Dalgleish AG Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies. Eur J Cancer. 2006 ; 42: 2318-2325.
    • (2006) Eur J Cancer , vol.42 , pp. 2318-2325
    • Sharma, R.A.1    Steward, W.P.2    Daines, C.A.3    Knight, R.D.4    O'Byrne, H.A.5    Dalgleish, A.G.6
  • 52
    • 33847293709 scopus 로고    scopus 로고
    • Bortezomib-induced peripheral neurotoxicity: A neurophysiological and pathological study in the rat
    • Cavaletti G., Gilardini A., Canta A., et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol. 2007 ; 204: 317-325.
    • (2007) Exp Neurol , vol.204 , pp. 317-325
    • Cavaletti, G.1    Gilardini, A.2    Canta, A.3
  • 53
    • 36049048587 scopus 로고    scopus 로고
    • Neurologic complications of chemotherapy agents
    • Kannarkat G., Lasher EE, Schiff D. Neurologic complications of chemotherapy agents. Curr Opin Neurol. 2007 ; 20: 719-725.
    • (2007) Curr Opin Neurol , vol.20 , pp. 719-725
    • Kannarkat, G.1    Lasher, E.E.2    Schiff, D.3
  • 54
    • 3042523914 scopus 로고    scopus 로고
    • Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: A retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer
    • Gamelin L., Boisdron-Celle M., Delva R., et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res. 2004 ; 10: 4055-4061.
    • (2004) Clin Cancer Res , vol.10 , pp. 4055-4061
    • Gamelin, L.1    Boisdron-Celle, M.2    Delva, R.3
  • 55
    • 34548544244 scopus 로고    scopus 로고
    • Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity
    • Hochster H., Grothey A., Childs B., et al. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol. 2007 ; 25: 4028-4029.
    • (2007) J Clin Oncol , vol.25 , pp. 4028-4029
    • Hochster, H.1    Grothey, A.2    Childs, B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.